Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02397408 · ClinicalTrials.gov registry record · Phase 2
11C- and 18F-Choline PET/MR Imaging for Prostate Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02397408 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 18 participants.
The verdict
NCT02397408, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C- and 18F-choline PET/MR may help find and diagnose prostate cancer and find out how far the disease has spread.
Interventions
- DRUG Carbon C 11 Choline
- DRUG Fluorine F 18 Choline
- PROCEDURE Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2015-04-09 |
| Est. Completion | 2015-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02397408
The ClinicalTrials.gov registry entry for NCT02397408 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carbon C 11 Choline is the first listed.
NCT02397408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02397408 about?
NCT02397408 is a clinical study titled "11C- and 18F-Choline PET/MR Imaging for Prostate Cancer". This phase II trial studies how well 11C-choline (carbon C 11 choline) and 18F-choline (fluorine F 18 choline) positron emission tomography/magnetic resonance (PET/MR) imaging works in diagnosing patients with unfavorable intermediate to high-risk prostate cancer. Diagnostic procedures, such as 11C-...
What is the current status of trial NCT02397408?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2015-04-09. Estimated completion is 2015-06-30.
What interventions are being tested in trial NCT02397408?
The interventions under investigation include: Carbon C 11 Choline (DRUG), Fluorine F 18 Choline (DRUG), Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI) (PROCEDURE).
Who is sponsoring clinical trial NCT02397408?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.